2025-04-23 - Analysis Report
## Albemarle Corp (ALB) Stock Report

**0. Summary of Key Figures:**

* **Cumulative Return (ALB):** 6.39%
* **Cumulative Return (VOO):** 76.31%
* **Return Difference (ALB vs VOO):** -69.9%
* **Relative Divergence:** 7% (meaning the current underperformance is at the 7th percentile of historical underperformance relative to VOO)
* **Current Price:** $54.77
* **5-Day Moving Average:** $53.46
* **20-Day Moving Average:** $62.34
* **60-Day Moving Average:** $73.02
* **RSI:** 31.9
* **PPO:** -0.96
* **Market Risk Indicator (MRI):** 0.435 (Medium Risk)
* **Expected Return (vs S&P 500, long-term):** 14414.5%


**1. Company Overview and Performance Comparison:**

Albemarle Corp is a global leader in the production and sale of lithium and bromine-based specialty chemicals.  The provided data shows that ALB significantly underperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return of 6.39% compared to VOO's 76.31%. This represents a substantial -69.9% difference. The relative divergence of 7% indicates that while significantly underperforming, this level of underperformance is relatively mild compared to historical extremes.

The Alpha and Beta analysis shows highly variable performance over time. While some periods show strong outperformance (high positive alpha), others show extreme underperformance (high negative CAGR and large negative alpha).  The high beta values suggest significant market sensitivity.  The high maximum drawdown (MDD) across all periods indicates substantial risk.


**2. Recent Price Movement:**

The current price of $54.77 is below all three moving averages (5-day, 20-day, and 60-day), suggesting a downtrend.  The recent price increase of 3.3% from the previous close might be interpreted as a short-term bounce, especially given the significant distance to the moving averages.  The negative PPO and low RSI further support the bearish sentiment.

**3. Technical Indicators and Expected Return:**

The RSI of 31.9 suggests the stock is in oversold territory. The negative PPO (-0.96) confirms bearish momentum. The positive change in relative divergence (0.5) indicates a recent short-term upward trend, however this should be interpreted with caution given the overall downtrend suggested by the moving averages.  The MRI value of 0.435 suggests a medium level of risk. The exceptionally high expected return of 14414.5% is likely an outlier or requires further investigation and clarification on calculation methodology, as it is not consistent with the historical performance data.  This figure should be treated with extreme skepticism.

**4. Recent Earnings Analysis:**

The recent earnings data shows a mixed picture.  While Q4 2023 showed strong positive EPS and revenue, the subsequent quarters of 2024 have shown significant losses. This sharp decline in profitability warrants further investigation into the underlying causes. There is a duplicate entry for 2024-11-06.

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -9.45  | $1.35 B      |
| 2024-07-31 | -1.96  | $1.43 B      |
| 2024-05-01 | -0.08  | $1.36 B      |
| 2023-11-01 | 2.58   | $2.31 B      |
| 2024-11-06 | 2.58   | $2.31 B      |


**5. Financial Information Analysis:**

The financial statements reveal a significant decline in revenue and profitability from Q4 2023 to the subsequent quarters in 2024.  Profit margins went from a positive 2.86% to sharply negative values. The equity also decreased, and ROE shows similar volatility with a trend towards negative values in the recent quarters. This suggests a potentially serious issue affecting the company's financial health, which requires further investigation.


| Quarter    | Revenue | Profit Margin | Equity    | ROE       |
|------------|----------|---------------|-----------|-----------|
| 2024-12-31 | $1.23B   | 11.22%        | $9.96B    | 0.76%     |
| 2024-09-30 | $1.35B   | -7.68%        | $10.24B   | -10.44%   |
| 2024-06-30 | $1.43B   | -0.74%        | $11.22B   | -1.68%    |
| 2024-03-31 | $1.36B   | 2.86%         | $11.53B   | 0.02%     |
| 2023-12-31 | $2.36B   | -29.88%       | $9.41B    | -6.56%    |


**6. Overall Conclusion:**

ALB has significantly underperformed the S&P 500 recently, showing considerable volatility and a recent decline in profitability. While some technical indicators suggest oversold conditions and a short-term bounce, the overall trend is bearish. The substantial negative earnings in recent quarters and the decline in financial metrics raise serious concerns about the company's financial health. Further investigation into the causes of these issues is crucial before making any investment decisions.  The extremely high expected return figure should be disregarded without a clear explanation of its derivation.  A thorough analysis of the underlying business factors is needed to assess the long-term prospects of Albemarle Corp.
